IN THE NEWS

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

January 7th, 2020|

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer Launch Preparation Underway for Lonafarnib in Progeria Market Development Activities Advancing for HDV Program PALO ALTO, Calif., January 7, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Eldon Mayer as Executive Vice President and Chief Commercial Officer.  Mr. Mayer is a [...]

Eiger Updates on 2019 Progress and 2020 Milestones Expected

January 6th, 2020|

Eiger Updates on 2019 Progress and 2020 Milestones Expected Progeria Rolling NDA Planned for Completion in 1Q 2020 HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 Commercial Focus on Progeria Launch Preparation and HDV Market Building Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif., January 6, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and [...]

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

December 17th, 2019|

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Rolling NDA Submission Planned for Completion in First Quarter 2020 Marketing Authorization Application (MAA) to EMA Planned in First Quarter 2020 PALO ALTO, Calif., December 16, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has initiated [...]